Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

The semaglutide dosing chart below shows the dosing schedule ... a different GLP-1 receptor agonist to help with weight loss. Zepbound (tirzepatide) and Saxenda (liraglutide) are two other options ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage study of its investigational candidate, amycretin, in overweight/obese ...

Zepbound (tirzepatide) is a prescription injection that comes as a single-dose pen or single-dose vial. If your doctor prescribes Zepbound to you and you need to travel, there are certain things ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

Some peptides help promote weight loss by helping to regulate blood sugar levels, metabolism, and appetite. These medications may cause side effects and people must have a prescription to take them.